InterVenn Shifts Direction Again, From Immunotherapy Focus to Cancer Screening
Just months after launching a test for guiding immunotherapy, the glycoproteomics firm has switched priorities to a colorectal cancer screening assay.
Stanford University United States South San Francisco Intervenn Biosciences Simplipro Colon John Leite
Source: 360dx.com